# US 2026/0007697 A1 · New chimeric antigen receptor (car) cells and medical uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0007697 A1
- Document ID: US20260007697A1
- Status: Published application
- Kind: A1
- Application number: 18/844,776
- Filed: 2023-03-08
- Published: 2026-01-08
- Earliest claimed: 2022-03-08
- Applicants: FundacióN Para La InvestigacióN MéDica Aplicada
- Inventors: Juan José LASARTE SAGASTIBELZA; Teresa LOZANO MOREDA; Celia MARTÍN OTAL
- Web page: https://patentgrep.com/patent/US20260007697A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- C12N 5/0636: {T lymphocytes}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/18: against material from animals or humans
- C12N 15/86: Viral vectors
- A61K 2239/17: Hinge-spacer domain
- A61K 2239/21: Transmembrane domain
- A61K 2239/22: Intracellular domain
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/03: containing a transmembrane segment
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to a new Chimeric Antigen Receptor (CAR) targeting the extra-domain A of fibronectin (EDA), to nucleic acid sequences and vectors encoding thereof, and host cells expressing the same. It further relates to methods of producing thereof, pharmaceutical compositions, kits, methods of treatment, and combination therapies using thereof.

## Claims

### Claim 1

A chimeric receptor nucleic acid comprising:
a) a polynucleotide coding for a ligand binding domain comprising an extra-domain A of fibronectin (EDA) targeting-moiety, wherein the EDA targeting moiety is an antibody fragment comprising:
i. a VH domain comprising a HCDR1 consisting of SEQ ID NO: 1, a HCDR2 consisting of SEQ ID NO: 2 and a HCDR3 consisting of SEQ ID NO: 3;
ii. a VL domain comprising a LCDR1 consisting of SEQ ID NO: 4, a LCDR2 consisting of SEQ ID NO: 5 and a LCDR3 consisting of SEQ ID NO: 6;
b) a polynucleotide coding for a transmembrane domain; and
c) a polynucleotide coding for an intracellular signaling domain.

### Claim 2 (depends on 1)

The chimeric receptor nucleic acid according to claim 1, wherein the EDA targeting moiety is a scFv comprising a VH domain consisting of SEQ ID NO: 7 and a VL domain consisting of SEQ ID NO: 8.

### Claim 3 (depends on 1)

The chimeric receptor nucleic acid according to claim 1, wherein the transmembrane domain comprises the transmembrane domain of CD28, CD3, CD45, CD4, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, or CD154.

### Claim 4 (depends on 1)

The chimeric receptor nucleic acid according to claim 1, wherein the intracellular signaling domain comprises the intracellular domain of CD3ζ, FcRγ, CD3γ, CD3δ, CD3ε, CD5, CD22, CD79a, CD79b, or CD66b.

### Claim 5 (depends on 1)

The chimeric receptor nucleic acid according to claim 1, wherein the chimeric receptor further comprises a costimulatory signaling domain.

### Claim 6 (depends on 1)

The chimeric receptor nucleic acid according to claim 1, wherein, the chimeric receptor comprises:
(i) a scFv comprising a VH domain and VL domain, wherein the VH domain comprises a HCDR1 consisting of SEQ ID NO: 1, a HCDR2 consisting of SEQ ID NO: 2 and a HCDR3 consisting of SEQ ID NO: 3; and the VL domain comprises a LCDR1 consisting of SEQ ID NO: 4, a LCDR2 consisting of SEQ ID NO: 5 and a LCDR3 consisting of SEQ ID NO: 6;
(ii) a hinge or spacer region comprising or consisting of SEQ ID NO: 10;
(iii) a transmembrane domain comprising or consisting of SEQ ID NO: 11;
(iv) an intracellular signaling domain comprising or consisting of SEQ ID NO: 12; and
(v) a costimulatory signaling domain comprising or consisting of SEQ ID NO: 13.

### Claim 7 (depends on 1)

A chimeric receptor polypeptide coded for by a chimeric receptor nucleic acid according to claim 1.

### Claim 8 (depends on 1)

An expression vector comprising a chimeric receptor nucleic acid according to claim 1.

### Claim 9 (depends on 1, 8)

A host cell comprising a nucleic acid according to claim 1 or an expression vector of claim 8.

### Claim 10 (depends on 9)

The host cell according to claim 9, wherein the host cell is
a) a CD8+ T lymphocyte cell selected from the group consisting of naïve CD8+ T cells, stem cell memory CD8+ T cells, central memory CD8+ T cells, effector memory CD8+ T cells and bulk CD8+ T cells; and/or
b) a CD4+T lymphocyte cell selected from the group consisting of naïve CD4+ T cells, stem cell memory CD4+ T cells, central memory CD4+ T cells, effector memory CD4+ T cells and bulk CD4+ T cells.

### Claim 11 (depends on 9)

A pharmaceutical composition comprising a host cell claim 9, such as a plurality thereof, and a pharmaceutically acceptable excipient, diluent or carrier.

### Claim 12

(canceled)

### Claim 13

A method of treating an EDA-positive cancer in a subject wherein said method comprises administering a therapeutically effective amount of a chimeric receptor nucleic acid comprising:
a) a polynucleotide coding for a ligand binding domain comprising an extra-domain A of fibronectin (EDA) targeting-moiety;
b) a polynucleotide coding for a transmembrane domain; and
c) a polynucleotide coding for an intracellular signaling domain; or
a chimeric receptor polypeptide coded for thereby;
an expression vector comprising the chimeric receptor nucleic acid;
a host cell comprising the chimeric receptor nucleic acid or the expression vector; or
a pharmaceutical composition comprising any thereof and further comprising and a pharmaceutically acceptable excipient, diluent or carrier.

### Claim 14 (depends on 1, 13)

The method of treating an EDA-positive cancer in a subject according to claim 13, wherein the chimeric receptor nucleic acid comprises the chimeric receptor nucleic acid of claim 1.

### Claim 15 (depends on 13)

The method of treating an EDA-positive cancer in a subject according to claim 13, wherein said EDA-positive cancer is colorectal cancer, liver cancer, pancreatic cancer, breast cancer, ovary cancer, prostate cancer, testis cancer, bladder cancer, glioma, melanoma, lymphoma, head and neck cancer, teratocarcinoma, or cholangiocarcinoma.

### Claim 16 (depends on 1)

The chimeric receptor nucleic acid according to claim 1, further comprising a polynucleotide coding for a hinge or spacer region.

### Claim 17 (depends on 1)

The chimeric receptor nucleic acid according to claim 1, wherein the antibody fragment is a single chain Fv (scFv).

### Claim 18 (depends on 2)

The chimeric receptor nucleic acid according to claim 2, wherein said EDA targeting moiety is a scFv comprising or consisting of SEQ ID NO: 9.

### Claim 19 (depends on 3)

The chimeric receptor nucleic acid according to claim 3, wherein the transmembrane domain comprises the transmembrane domain of CD8.

### Claim 20 (depends on 4)

The chimeric receptor nucleic acid according to claim 4, wherein the intracellular signaling domain comprises the intracellular domain of CD35.

### Claim 21 (depends on 5)

The chimeric receptor nucleic acid according to claim 5, wherein the costimulatory signaling domain comprises the intracellular domain of CD27, CD28, 41BB (CD137), CD134, CD30, CD40, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, CD278 or CD276.

### Claim 22 (depends on 5)

The chimeric receptor nucleic acid according to claim 5, wherein the costimulatory signaling domain comprises the intracellular domain of 41BB (CD137).

### Claim 23 (depends on 6)

The chimeric receptor nucleic acid according to claim 6, wherein in the CAR nucleic acid the coding polynucleotide of the EDA-targeting ScFv is operably linked to the coding polynucleotide of the hinge or spacer region which is operably linked to the transmembrane region coding polynucleotide which is operably linked to the polynucleotide coding for the costimulatory signaling domain which is operably linked to the intracellular signaling domain coding polynucleotide.

### Claim 24 (depends on 8)

The expression vector according to claim 8, wherein the vector is a viral vector.

### Claim 25 (depends on 24)

The expression vector according to claim 24, wherein the viral vector is a γ-retroviral or lentiviral vector.

### Claim 26 (depends on 9)

The host cell according to claim 9, wherein the host cell is a T lymphocyte cell or a natural killer (NK) cell.

### Claim 27 (depends on 13)

The method of treating an EDA-positive cancer in a subject according to claim 13, wherein the polynucleotide coding for a ligand binding domain comprising an extra-domain A of fibronectin (EDA) targeting-moiety is a single chain Fv (scFv).

### Claim 28 (depends on 13)

The method of treating an EDA-positive cancer in a subject according to claim 13, wherein the chimeric receptor nucleic acid further comprises a polynucleotide coding for a hinge or spacer region.

### Claim 29 (depends on 13)

The method of treating an EDA-positive cancer in a subject according to claim 13, wherein the chimeric receptor nucleic acid further comprises a polynucleotide coding for a costimulatory signaling domain.
